APP and Alzheimer disease: However, LC1405 treatment suppressed the phosphorylation in APP/PS1 mice (p-AKT: 1.56 ± 0.04 ng/mg protein vs. 2.58 ± 0.09 ng/mg protein, 1.61 ± 0.05 ng/mg protein vs. 2.91 ± 0.15 ng/mg protein; p-GSK3β: 3.44 ± 0.09 ng/mg protein vs. 5.54 ± 0.40 ng/mg protein, 3.22 ± 0.11 ng/mg protein vs. 5.82 ± 0.31 ng/mg protein; all p < 0.001), suggesting that LC1405 might be able to reverse the activated signaling of AKT/GSK3β in AD.